Genmab | GEN - Cash And Equivalent

Stock Price
1,750.50
Daily Change
37.50 2.19%
Monthly
-6.01%
Yearly
37.24%
Q2 Forecast
1,596.02

Genmab reported DKK1.72B in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Agios Pharmaceuticals USD 89.13M 3.58M Dec/2025
Almirall EUR 337.77M 14.83M Dec/2025
Amarin USD 122.8M 25.08M Sep/2025
Amgen USD 9.13B 316M Dec/2025
argenx SE USD 4.3B 2.21B Sep/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
Bayer EUR 5.9B 1.34B Sep/2025
BioMarin Pharmaceutical USD 1.31B 61.57M Dec/2025
Demant DKK 1.33B 188M Dec/2025
Exelixis USD 482.49M 106.19M Dec/2025
Fresenius Medical Care EUR 1.58B 326.57M Dec/2025
Galapagos EUR 87.87M 23.41M Dec/2025
Genmab DKK 1.72B 46M Dec/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
GN Store Nord DKK 767M 363M Sep/2025
GRIFOLS EUR 558.69M 194.13M Jun/2025
Hikma Pharmaceutical USD 236M 48M Jun/2025
Insmed USD 510.44M 175.68M Dec/2025
Lonza CHF 719M 188M Dec/2025
Merck EUR 2.25B 1.08B Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
UCB EUR 1.57B 1.14B Dec/2024